Dirk Lange (KBI)
December 3, 2020 11:04 AM EST
Outsourcing

KBI plans $150M fa­cil­i­ty in Re­search Tri­an­gle Park with mys­tery co-in­vestor

Nicole DeFeudis

Editor

A month af­ter un­veil­ing plans for a new man­u­fac­tur­ing fa­cil­i­ty in Gene­va, KBI Bio­phar­ma has al­ready pegged the lo­ca­tion for its next site: a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times